Sionna Therapeutics (NASDAQ:SION - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17), Zacks reports.
Sionna Therapeutics Stock Down 0.1%
Shares of SION traded down $0.01 during mid-day trading on Friday, reaching $13.43. The company's stock had a trading volume of 190,842 shares, compared to its average volume of 196,234. Sionna Therapeutics has a 1-year low of $7.26 and a 1-year high of $25.19. The business's 50-day moving average price is $11.95.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on SION. Stifel Nicolaus began coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price target on the stock. TD Cowen began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating on the stock. Finally, Guggenheim began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $45.00 target price on the stock.
Get Our Latest Stock Analysis on Sionna Therapeutics
Institutional Trading of Sionna Therapeutics
An institutional investor recently bought a new position in Sionna Therapeutics stock. Woodline Partners LP purchased a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 80,000 shares of the company's stock, valued at approximately $837,000. Woodline Partners LP owned about 0.18% of Sionna Therapeutics as of its most recent filing with the Securities and Exchange Commission.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
